LY3437943 · GLP-1/GIP/Glucagon Triple Agonist
Triple-agonist GLP-1/GIP/glucagon receptor agonist. Most studied compound in metabolic research.
Retatrutide (LY3437943) is a GIP/GLP-1/glucagon triple receptor co-agonist in Phase 3 clinical investigation. Phase 2 NEJM data (2023) demonstrated up to 24.2% mean body weight reduction at 48 weeks, the highest reported for any incretin-class compound.
Store lyophilized at -20°C for 12–24 months. Reconstituted in BAC water: refrigerate at 2–8°C, use within 4–6 weeks.